{
    "nct_id": "NCT05207709",
    "official_title": "A Phase III, Multicenter, Open-label Study of Ribociclib vs. Palbociclib in Patients With Advanced Hormone Receptor-positive/HER2-negative/HER2-Enriched Breast Cancer - HARMONIA Trial",
    "inclusion_criteria": "* Histologically documented HR-positive and HER2-negative breast cancer by local testing\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.\n* advanced (loco regionally recurrent not amenable to curative therapy or metastatic) breast cancer.\n* Availability of FFPE tumor block for biomarker analysis, obtained during metastatic period.\n* HER2-E or Basal-like subtype as per central PAM50 analysis.\n* Measurable disease or non-measurable disease, as defined by RECIST v1.1\n* Adequate hematologic and end-organ function\n* Patient must be willing and able to comply with scheduled visits, treatment plans, laboratory tests, and other trial procedures.\n* Women of childbearing potential must have confirmed negative serum pregnancy test within 7 days prior to randomization.\n* Women of CBP must be willing to use highly effective methods of contraception.\n* Patient must have a 6-lead or 12-lead ECG with ALL of the following parameters at screening:\n\n  * QTcF interval (QT interval using Fridericia's correction) at screening < 450 msec.\n  * Resting heart rate 50-90 beats per minute (determined from the ECG).\n\nMain\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Prior therapy with any CDK4/6 inhibitors.\n* Patient has received prior treatment with chemotherapy for advanced/metastatic breast cancer",
    "miscellaneous_criteria": "Main"
}